Abstracts tagged "Vasculitis"

Abstract Number: 0759 • ACR Convergence 2025
Distinct differences between giant cell arteritis diagnosed by fluorodeoxyglucose (FDG) positron emission tomography (PET) versus temporal artery biopsy-a comparative cohort study
Sehreen Mumtaz¹, Lerone Clark², Archit Srivastava², Hannah Langenfeld³, Andrew C. Hanson³, Cynthia Crowson⁴, Andy Abril², Nouran Eshak⁵, Megan Sullivan⁶, Matthew Koster³ and Kenneth Warrington³, ¹Mayo Clinic Florida, Jacksonville, FL, ²Mayo Clinic, Florida, Jacksonville, FL, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Stewartvillle, MN, ⁵Mayo Clinic, Arizona, Scottsdale, AZ, ⁶Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Giant cell arteritis (GCA) is clinically heterogenous, and the presenting manifestations may influence diagnostic testing. The aim of this study was to evaluate the…
Abstract Number: 0730 • ACR Convergence 2025
Levels of Disease Activity and Their Relationship With Health-Related Quality of Life In ANCA-Associated Vasculitis Patients: Data from the Almenara Vasculitis Cohort
Victor Pimentel-Quiroz¹, Alvaro Oyarce-Calderón², Allison Figueroa-Sánchez³, Leonor León-Yaurimucha³, Rocío Gamboa-Cárdenas⁴, Zoila Rodríguez-Bellido⁵, Risto Perich-Campos⁶, Graciela Alarcón⁷ and Manuel Ugarte-Gil⁸, ¹Universidad Científica del Sur, San Isidro, Peru, ²Hospital Nacional Guillermo Almenara Irigoyen, San Miguel, Lima, Peru, ³Universidad Científica del Sur, Lima, Peru, ⁴Universidad Científica del Sur, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁶Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ⁷The University of Alabama at Birmingham, Oakland, CA, ⁸Universidad Cientifica del Sur, Lima, Peru
Background/Purpose: It is known that health-related quality of life (HRQoL) in patients with ANCA-associated vasculitis (AAV) is impaired. Categories of disease activity levels have been…
Abstract Number: 2700 • ACR Convergence 2025
Neutrophil Transcriptomics and Maturation Pathways in VEXAS Syndrome
Chloe Palmer¹, Gustaf Wigerblad², Tom Hill³, Benjamin Turturice¹, Urvashi Kaundal¹, Paul Schaughency³, Bhavisha Patel⁴, Emma Groarke⁵, Neal Young⁵, Stefania Dell'orso¹ and Peter Grayson⁶, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²National Institutes of Health, Stockholm, Sweden, ³NIAID, NIH, Bethesda, MD, ⁴National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Beltsville, MD, ⁵National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, ⁶National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a severe adult-onset inflammatory disease caused by somatic mutations of the ubiquitin-like modifier activating enzyme…
Abstract Number: 2504 • ACR Convergence 2025
Variables Associated with In-Hospital Mortality in Adult Eosinophilic Granulomatosis with Polyangiitis from the National Inpatient Sample Database 2017-2021
Anuya Natu¹, Isadora Small², Shilpa Arora³ and Augustine Manadan⁴, ¹John H Stroger, Jr. Hospital of Cook County, Chicago, IL, ²The Latin School of Chicago, Chicago, IL, ³Cook County Hospital, Chicago, IL, ⁴Rush University Medical Center, Chicago, IL
Background/Purpose: Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare systemic vasculitis that can lead to significant morbidity and mortality. This study aims to evaluate the…
Abstract Number: 1623 • ACR Convergence 2025
The Association of Calprotectin with Vascular Injury and Remodeling in Clinically-Isolated Aortitis
Katarina Kmetova¹, Gavin Poppei², Kavya Sugur³, Julia Ford⁴, Wenying Liang⁴, Emily Chong⁴, Srilakshmi Yalavarthi⁴, NaveenKumar Somanathapura⁴, Nataliya Milman⁵, Peter Merkel⁶, Ora Singer⁷ and Yu (Ray) Zuo⁴, ¹Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ²University of Michigan, Ann arbor, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, ⁴University of Michigan, Ann Arbor, MI, ⁵the Ottawa Hospital, Ottawa, ON, Canada, ⁶University of Pennsylvania, Philadelphia, PA, ⁷University of Michigan, Huntington Woods, MI
Background/Purpose: Clinically-isolated aortitis (CIA), defined as inflammation of the aortic wall in the absence of extra-aortic arterial involvement, systemic vasculitis, or other associated autoimmune disease,…
Abstract Number: 1075 • ACR Convergence 2025
Racial Differences in Management and Clinical Outcomes of Giant-Cell Arteritis: A Real-World Propensity-Matched Study
Michael Hamilton¹, Justin Riley Lam², Emmanuel Otabor³, Laith Alomari³, Maxim Barnett³, Fabian Rodriguez Quinonez⁴ and Irene Tan⁵, ¹Jefferson Einstein Hospital, Philadelphia, Philadelphia, PA, ²Jefferson Einstein Hospital, Philadelphia, PA, ³Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, ⁴Einstein Medical Center Philadelphia, Philadelphia, PA, ⁵Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA
Background/Purpose: Giant-cell arteritis (GCA) is usually described in people of Northern-European ancestry, and little is known about outcomes in Black and Hispanic (B-His) patients. Using…
Abstract Number: 0758 • ACR Convergence 2025
Association Between Baseline IL-6 Levels and the Clinical Phenotype of Giant Cell Arteritis
Raquel Ugena-García¹, Clara Churtichaga Domenech², Judith Vidal-Ripoll², Francina salabert-Carreras², Cristina Calomarde-Gómez¹, Cristina Rocamora-Gisbert³, Irene Peralta-García⁴, Niccolo Viveros², Anne Riveros Frutos³, Ivette Casafont-Solé¹ and Judit Font-Urgelles¹, ¹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital Germans Trias i Pujol, Barcelona, ³Hospital Germans Trias i Pujol, Barcelona, Spain, ⁴Karolinska Institutet, Clinical Epidemiology Division, Department of Medicine Solna. Karolinska University Hospital, Medical Unit of Gastroenterology, Dermatology, Rheumatology. Theme Inflammation and Ageing, Stockholm, Sweden
Background/Purpose: Giant cell arteritis (GCA) is the most common form of vasculitis in patients over the age of 50. Interleukin-6 (IL-6) has been shown to…
Abstract Number: 0727 • ACR Convergence 2025
Higher rates of severe sensorineural hearing loss in granulomatosis with polyangiitis (GPA) compared to other antineutrophil cytoplasmic antibody (ANCA) associated vasculitis
Sehreen Mumtaz¹, Kindalem Fentie², Joseph Parker², Emily Craver¹, Vikas Majithia³ and Andy Abril⁴, ¹Mayo Clinic Florida, Jacksonville, FL, ²Mayo Clinic, Florida, Jacksonville, FL, ³Mayo Clinic Hospital, Jacksonville, FL, ⁴Mayo Clinic Florida, Jacksonville
Background/Purpose: Hearing loss in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is one of the commonly reported manifestations of organ damage in AAV with predominantly…
Abstract Number: 2610 • ACR Convergence 2025
Imaging remission in aortitis associated with giant cell arteritis. Multicenter study with tocilizumab in monotherapy and combined therapy
Adrian Martin-Gutierrez¹, Javier Loricera², Diana Prieto-Peña³, Vicente Aldasoro Cáceres⁴, Olga Maiz⁵, Eugenio de Miguel⁶, Eva Galíndez Agirregoikoa⁷, Ivan Ferraz Amaro⁸, Santos Castañeda⁹ and Ricardo Blanco¹⁰, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ⁴Hospital Universitario de Navarra, Pamplona, Spain, ⁵Hospital Universitario de Donosti, Donostia, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain, ⁷BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ⁸Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁹Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹⁰Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Aortitis is a frequent and potential severe complication of giant cell arteritis (GCA)(GCA-aortitis). Tocilizumab (TCZ) was approved for the treatment of GCA, but its…
Abstract Number: 2218 • ACR Convergence 2025
Pregnancy Outcomes and Placental Findings in Women with IgA Vasculitis: A Case-Control Study
Edgar Iván Mendoza Ríos, María Del Carmen Zamora Medina, Mario Isaac Lumbreras Márquez, Diana Yazmin Copado mendoza, Oralia Alejandra Orozco Guillén, Maria José rodríguez Sibaja, Martha Leticia Palafox Vargas and Sandra Acevedo gallegos, Instituto Nacional de Perinatología, Mexico City, Distrito Federal, Mexico
Background/Purpose: IgA vasculitis (IgA-V) is a systemic vasculitis involving small vessels, most frequently affecting children. There is few information about pregnancy outcomes in women with…
Abstract Number: 1621 • ACR Convergence 2025
Temporal Association Between Viral Positivity Rates and Kawasaki Disease Incidence at a Large Tertiary Center
Jessica Nguyen¹, Duc Nguyen¹, Ankona Banerjee², Kenneth Nobleza², Denver Niles² and Marietta De Guzman¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston
Background/Purpose: Kawasaki disease (KD) is a systemic vasculitis associated with the development of coronary artery aneurysms predominantly affecting children less than 5 years of age.…
Abstract Number: 1074 • ACR Convergence 2025
Racial Disparities in Cardiovascular, Ocular, and Treatment Outcomes in US Patients with Behçet’s Disease: A Propensity-Matched Real-World Analysis
Michael Hamilton¹, Justin Riley Lam², Emmanuel Otabor³, Laith Alomari³, Maxim Barnett³, Shahrzad Abdollahi² and Irene Tan⁴, ¹Jefferson Einstein Hospital, Philadelphia, Philadelphia, PA, ²Jefferson Einstein Hospital, Philadelphia, PA, ³Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, ⁴Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA
Background/Purpose: Racial/ethnic disparities in Behçet’s disease (BD) outcomes are largely undocumented in the United States. Given known differences in disease expression across populations globally, we…
Abstract Number: 0756 • ACR Convergence 2025
Stroke Characteristics in Giant Cell Arteritis and Takayasu Arteritis: A Multicenter Cohort Study of 108 Patients
Omar Dhrif¹, Charlotte Caudron², Simon Parreau³, Eric Liozon³, Adrien Mirouse⁴, Jean-François Alexandra⁵, Laurent Sailler⁶, Mathieu Groh⁷, Hubert De Boysson⁸, Mikael Ebbo⁹, Cloé Comarmond¹⁰, Cécile Audrey Durel¹¹, Juliette Woessner¹², Pierre-André Jarrot¹³, Kévin Didier¹⁴, Goulabchand Radjiv¹⁵, Cacoub Patrice¹⁶, Bernard Bonnotte¹⁷, David Saadoun¹⁶ and Maxime Samson¹, ¹CHU Dijon Bourgogne, Dijon, France, ²CENTRE HOSPITALIER UNIVERSITAIRE DE DIJON, Paris, France, ³CHU de Limoges, Limoges, France, ⁴Médecine Interne et Immunologie Clinique, Groupe Hospitalier Pitié-Salpêtrière, APHP, Paris, Paris, France, ⁵Internal Medicine, Hôpital Bichat, APHP, Paris, France, ⁶CHU Toulouse, Toulouse, France, ⁷Hôpital Foch, Suresnes, France, ⁸Internal Medicine, CHU Caean, Caen, France, ⁹Internal Medicine, Marseille-APHM, hôpital La Timone, Marseille, France, ¹⁰Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM U⁹⁴², Paris, France, ¹¹Médecine Interne, Hôpital Saint Joseph Saint Luc, Lyon, Lyon, France, ¹²Médecine Interne, CH d’Avignon, Avignon, Avignon, France, ¹³Médecine Interne, Hôpital de la Conception, APHM, Marseille, Marseille, France, ¹⁴Médecine Interne, CHU Reims, Reims, Reims, France, ¹⁵Médecine Interne, CHU Nîmes, Nîmes, Nîmes, France, ¹⁶Department of Internal Medicine and Clinical Immunology, Sorbonne Universités, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Centre national de références Maladies Autoimmunes et systémiques rares, Centre national de références Maladies Autoinflammatoires rares et Amylose inflammatoire (CEREMAIA), INSERM, UMR S⁹⁵⁹, Immunology-Immunopathology-Immunotherapy (I³), Paris, France, Paris, France, ¹⁷Internal medicine and clinical immunology, Université Bourgogne Europe , CHU Dijon Bourgogne, Dijon, France
Background/Purpose: In giant cell arteritis (GCA) and Takayasu arteritis (TA), strokes occur in approximately 7.4% and 15.8% of cases, respectively. Although these two large-vessel vasculitides…
Abstract Number: 0728 • ACR Convergence 2025
Incidence and Clinical Characteristics of ANCA-Associated Vasculitis: A Nationwide Study in Spain
Susana Romero-Yuste¹, Marta Domínguez-Álvaro², Antonio Fernández-Nebro³, Miquel Blasco⁴, Beatriz Ventosa⁵, Javier Narváez⁶, Gema Fernández⁷, Iñigo Rúa-Figueroa⁸, Desirée Luis-Rodríguez⁹ and Manuel Macía¹⁰, ¹University Hospital Complex of Pontevedra, Pontevedra, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Hospital Regional Universitario de Malaga, Malaga, Spain, Malaga, Spain, ⁴Hospital clinic Barcelona, Barcelona Spain, Spain, ⁵Spanish Society of Rheumatology, Madrid, Spain, ⁶Hospital Universitario de Bellvitge, Barcelona, Spain, ⁷Hospital la Paz, Madrid, Madrid, Spain, ⁸Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ⁹Hospital Universitario Nuestra Señora de Candelaria, Tenerife, Spain, ¹⁰Hospital Universitario Nuestra Señora de Candelaria,, Tenerife, Spain
Background/Purpose: ANCA-associated vasculitides (AAV)—granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA), and microscopic polyangiitis (MPA)are rare but severe systemic vasculitides with significant morbidity and…
Abstract Number: 2584 • ACR Convergence 2025
Spatially Resolved Transcriptomics Reveal Macrophage Heterogeneity in Giant Cell Arteritis
Lea Dionet¹, Federica Pallotti², Margot Poux³, Quentin Delcros⁴, Nader Yatim⁵, Brian Soong⁶, Paul Breillat⁷, Kevin Chevalier⁸, claudie Cladière⁹, Patrick Bruneval¹⁰, Benoit Terris⁴, Alexis REGENT¹¹, Xavier Puéchal¹², Luc Mouthon¹³, Miriam Merad⁶, Olivia Lenoir¹⁴, Pierre-Louis Tharaux¹⁵, Maxime Samson¹⁶ and Benjamin Terrier¹⁷, ¹INSERM, Paris, France, ²Internal Medicine and Clinical Immunology, Rennes, France, ³Université de Paris, PARIS ⁰⁴EME, France, ⁴AP-HP, Paris, France, ⁵University of Paris-Cite, New York, NY, ⁶Mount Sinai School of Medicine, New York, ⁷INSERM, PARIS ¹⁷, Ile-de-France, France, ⁸Université Paris Cité, Montrouge, France, ⁹Marie et Louis Pasteur University, EFS, INSERM, UMR RIGHT, Besançon, France, Dijon, France, ¹⁰AP-HP, Paris, ¹¹Hopital Cochin, Paris, France, ¹²Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ¹³Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ¹⁴Paris Cardiovascular Research Center, Université Paris Cité, INSERM U⁹⁷⁰, Paris, France, PARIS, Ile-de-France, France, ¹⁵Paris Cardiovascular Research Center, Université Paris Cité, INSERM U⁹⁷⁰, Paris, France, PARIS, France, ¹⁶CHU Dijon Bourgogne, Dijon, France, ¹⁷Cochin Hospital, Paris, France
Background/Purpose: Giant cell arteritis (GCA) is a large-vessel vasculitis affecting individuals over 50 years of age. Current models implicate genetic susceptibility, immune senescence, activation of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].